港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

東陽光藥

56.250

-3.650-6.09%

成交量：330.86萬

成交額：1.84億

市值：324.37億

市盈率：- -

高：58.000

開：57.500

低：54.000

收：59.900

52周最高：62.300

52周最低：54.000

股本：5.77億

香港流通股本：4.64億

量比：1.35

換手率：0.71%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

資料載入中...

總覽公司新聞公告

政策東風賦能創新藥，東陽光藥港股敲鐘開啓新篇章

東陽光藥08月08日主力淨流出40.9萬元散户資金買入

每週醫刻｜藥品與耗材新一輪國採啓幕；違法短線交易，邁威生物董事長被重罰

熱烈祝賀穩正資產已投企業“東陽光藥”成功上市

投资界综合

數億融資到手！欣界能源 A 輪融資完成，產線擴建要來了 | 投資速遞

深耕宜都24年致力研發創新藥東陽光藥正式登陸港股

東陽光藥登陸港交所，上市首日未獲資金追捧

凤凰网财经

【新華財經調查】東陽光藥整合啓航多重利好衝擊百億市場

從“仿製”到“創新”：東陽光藥重構傳統Pharma價值邏輯

東陽光藥(06887.HK)整體上市，研產銷一體化重塑醫藥龍頭價值，市值有望快速突破500億

高科技之光照亮中國製造未來——東陽光集團高質量發展啓示錄

新股消息 | 東陽光藥(06887)完成港股創新式資本運作將於8月7日登陸港交所主板

上市生效決議獲近乎全票贊成通過，東陽光藥(06887)登陸港股進入最後倒計時

東陽光長江藥業(01558)與東陽光藥的合併協議獲股東大會通過預計東陽光藥將於8月7日上市

智通财经网

載譽而歸，東陽光藥(06887)發明專利斬獲湖北專利金獎！

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06887/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06887\",,,,,undefined,":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"東陽光藥","latestPrice":56.25,"timestamp":1754640484192,"preClose":59.9,"halted":0,"volume":3308573,"delay":0,"floatShares":463943215,"shares":576656047,"eps":0,"marketStatus":"已收盤","change":-3.65,"latestTime":"08-08 16:08:04","open":57.5,"high":58,"low":54,"amount":183736697,"amplitude":0.066778,"askPrice":56.25,"askSize":5100,"bidPrice":56.15,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1754875800000},"marketStatusCode":5,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":59.9,"openAndCloseTimeList":[[1754616600000,1754625600000],[1754629200000,1754640000000]],"volumeRatio":1.352016,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06887\",,,,,undefined,":{"symbol":"06887","floatShares":463943215,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.352016,"shares":576656047,"dividePrice":0,"high":58,"amplitude":0.066778,"preClose":59.9,"low":54,"week52Low":54,"pbRate":"--","week52High":62.3,"institutionHeld":0,"latestPrice":56.25,"committee":-0.672131,"eps":0,"divideRate":0,"volume":3308573,"delay":0,"ttmEps":0,"open":57.5,"prevYearClose":60.24,"prevWeekClose":60.24,"prevMonthClose":60.24,"prevQuarterClose":60.24,"fiveDayClose":60.24,"twentyDayClose":60.24,"sixtyDayClose":60.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06887\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06887","date":"2025-08-07","current":26.481481,"percent":1,"low":26.481481,"twenty":26.481481,"median":26.481481,"eighty":26.481481,"high":26.481481,"avg":26.481481,"sd":0,"marketCap":13973887076},"quantilePoints":[{"date":"2025-08-07","current":26.481481,"twenty":26.481481,"median":26.481481,"eighty":26.481481,"marketCap":13973887076}],"updateTime":1754644972177},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557256645","title":"政策東風賦能創新藥，東陽光藥港股敲鐘開啓新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2557256645","media":"市值风云","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557256645?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 18:11","pubTimestamp":1754647863,"startTime":"0","endTime":"0","summary":"中国创新药研发的第一梯队，已有3款1类新药上市，在研49款1类创新药。东阳光药在全球市场布局中展现出强劲的产品实力，拥有150款获批药物，近50款在研创新药。其中，在国内抗感染药物领域，东阳光药已位居行业前列。7月31日，国家医保局进一步明确“新上市药品首发价格机制”，为高水平创新药设立五年价格稳定期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808182902a47d10cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808182902a47d10cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["07226","HSCEI","06887","06978","BK1161","BK1574","HSTECH"],"gpt_icon":0},{"id":"2557552918","title":"東陽光藥08月08日主力淨流出40.9萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2557552918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557552918?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 16:15","pubTimestamp":1754640935,"startTime":"0","endTime":"0","summary":"08月08日, 东阳光药股价跌6.09%，报收56.25元，成交金额1.8亿元，换手率2.94%，振幅6.68%，量比0.00。该股近5个交易日下跌2.17%，主力资金累计净流出40.9万元；近20日主力资金累计净流出40.9万元，其中净流出天数为1日。|08月08日主力加仓幅度排名||#|股票简称|主力净额占比|#|伟鸿集团控股|2.97%|#|宏基集团控股|2.18%|#|嘉鼎国际集团|1.58%|#|...|...|#2359|东阳光药|-0.01%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173830a6dac138&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173830a6dac138&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887"],"gpt_icon":0},{"id":"2557491665","title":"每週醫刻｜藥品與耗材新一輪國採啓幕；違法短線交易，邁威生物董事長被重罰","url":"https://stock-news.laohu8.com/highlight/detail?id=2557491665","media":"财健道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557491665?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 15:40","pubTimestamp":1754638841,"startTime":"0","endTime":"0","summary":"政策1违法短线交易，迈威生物董事长被重罚8月5日，迈威生物发布公告称：公司董事长兼总经理刘大涛收到证监会上海监管局出具的《行政处罚决定书》。上海证监局决定对刘大涛给予警告，并处以60万元顶格罚款。然而对于违法交易、短线交易，目前仍执行60万元的罚款上限。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808154302a6da81ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808154302a6da81ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","688062","BK1191","LU2328871848.SGD","BK1500","06160","BK1583","BK1574","06887","01276","LU0307460666.USD","BK1588","LU1969619763.USD","LU0588546209.SGD","LU2543165471.USD","01093"],"gpt_icon":0},{"id":"2557548003","title":"熱烈祝賀穩正資產已投企業“東陽光藥”成功上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2557548003","media":"投资界综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557548003?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 14:24","pubTimestamp":1754634240,"startTime":"0","endTime":"0","summary":"2025年8月7日，稳正资产已投企业广东东阳光药业股份有限公司成功登陆港交所，股票代码为06887.HK，开盘价为57.5港元，收盘时市值达345亿港元。稳正资产创始合伙人陈义枫亲临上市庆典现场，与东阳光药团队共同见证这一辉煌时刻，并向企业致以最热烈的祝贺。稳正资产持续布局“东阳光虫草”、“东阳光药”等优质项目，并获得良好投资收益。从初识相伴到荣耀加冕，稳正资产有幸一路见证东阳光药以创新药企之姿昂首挺进国际资本市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808144006a47c96ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808144006a47c96ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887"],"gpt_icon":0},{"id":"2557128645","title":"數億融資到手！欣界能源 A 輪融資完成，產線擴建要來了 | 投資速遞","url":"https://stock-news.laohu8.com/highlight/detail?id=2557128645","media":"IT桔子","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557128645?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 12:06","pubTimestamp":1754625986,"startTime":"0","endTime":"0","summary":"今日，欣界能源正式完成了数亿元A轮融资。近日，芝诺科技成功完成了数千万元人民币的Pre-A轮融资，在此之前，芝诺科技已经完成了来自中信资本和嘉程资本等知名投资方的历史投资。近日，德沃智能获得A轮融资，金桥基金、朴棫基金投资。近日，恒大绿能完成对匠芯新材的战略投资，并已于近日完成工商变更。公司日前宣布完成5500万美元A轮融资，投资方为Elephant。近日，黑石集团Blackstone宣布与MannKind达成高达5亿美元战略融资协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808121728a6da223a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808121728a6da223a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887"],"gpt_icon":0},{"id":"2557597828","title":"深耕宜都24年 致力研發創新藥 東陽光藥正式登陸港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557597828","media":"荆楚网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557597828?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 07:08","pubTimestamp":1754608080,"startTime":"0","endTime":"0","summary":"湖北日报讯 8月7日，广东东阳光药业股份有限公司正式登陆香港联交所主板。目前，东阳光药在广东松山湖和湖北宜都拥有两大生产基地。2025年，东阳光新药迎来全面收获期，10个项目申报生产，7个产品获批上市。同时，抗抑郁新药磷酸嘧替佐酮片、治疗肺动脉高压新药东健强即将在宜都基地完成临床样品的生产；抗流感新药东安恩已在宜都基地完成临床申报批次样品的生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808071424a47bc7fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808071424a47bc7fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","06887","HSCEI","HSTECH","BK1574"],"gpt_icon":1},{"id":"2557353830","title":"東陽光藥登陸港交所，上市首日未獲資金追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2557353830","media":"凤凰网财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557353830?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 11:56","pubTimestamp":1754538990,"startTime":"0","endTime":"0","summary":"东阳光药周四通过介绍方式在港交所主板挂牌交易，开盘价为每股57.50港元，较其前一交易日完成最后交易的子公司东阳光长江药业每股60.24港元的收盘价折让约4.5%。根据安排，母公司东阳光药吸收合并其控股子公司东阳光长江药业，并以介绍方式整体登陆港交所。合并方案中，东阳光药向东阳光长江药业的小股东发行H股，换取其所持股份。港交所持续推动医药板块发展，香港已成为全球第二大医药与医疗科技融资中心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8lcbSWIti0C","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"gpt_icon":0},{"id":"2557567795","title":"【新華財經調查】東陽光藥整合啓航 多重利好衝擊百億市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2557567795","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557567795?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 10:11","pubTimestamp":1754532664,"startTime":"0","endTime":"0","summary":"在医药行业面临资本寒冬的背景下，东阳光药开辟了一条高效整合的创新路径，并释放多重利好，冲击百亿市场。吸收合并完成后，东阳光药再通过介绍方式实现上市。2024年，东阳光药实现营业收入40.19亿元，研发投入占总收入的比重超过20%。随着东阳光药在丙肝赛道的新突破，治疗价格将大大降低。销售网络助力东阳光药快速抢占市场，掘金丙肝百亿蓝海市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508071011109738aa21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508071011109738aa21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887"],"gpt_icon":0},{"id":"2557591560","title":"從“仿製”到“創新”：東陽光藥重構傳統Pharma價值邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2557591560","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557591560?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 07:31","pubTimestamp":1754523101,"startTime":"0","endTime":"0","summary":"与众多仓促转型的传统药企不同，东阳光药凭借其深厚的研发积淀、全球化布局的战略视野以及对肿瘤与罕见病领域的前瞻性布局，正在重构传统制药企业的价值逻辑。截至2025年，东阳光药在全球拥有150款获批药物，其中中国销售48款，海外市场销售23款。经过一系列的超前布局，东阳光药已构建起多元化且极具竞争力的产品管线。值得关注的是，东阳光药的伊非尼酮是国产首个进入III期临床的IPF原研新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807074928a6d76802&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807074928a6d76802&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887"],"gpt_icon":0},{"id":"2556832743","title":"東陽光藥(06887.HK)整體上市，研產銷一體化重塑醫藥龍頭價值，市值有望快速突破500億","url":"https://stock-news.laohu8.com/highlight/detail?id=2556832743","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556832743?lang=zh_tw&edition=fundamental","pubTime":"2025-08-04 18:59","pubTimestamp":1754305140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06887","BK4614","01558","159938","BK1191","BK1515","06978","YANG","BK1161","159992","BK1574","HSCEI","07226","HSTECH","09939"],"gpt_icon":0},{"id":"2555047680","title":"高科技之光照亮中國製造未來——東陽光集團高質量發展啓示錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2555047680","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555047680?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 15:41","pubTimestamp":1753947713,"startTime":"0","endTime":"0","summary":"《中国证券报》31日刊发文章《高科技之光照亮中国制造未来——东阳光集团高质量发展启示录》。此前，集团已有两家上市公司东阳光和东阳光长江药业，此次东阳光药吸收合并东阳光长江药业上市，标志着中国创新药迎来新锐力量，也意味着东阳光集团迈入全新发展阶段，向着更高目标迈进。在国家政策推动下，中国创新药加速迈向高质量发展的黄金时代。销售方面，东阳光药已建立覆盖全球的销售网络。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1324103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1515","01558","600673","BK0265","BK0003","BK1191","BK0028","BK0070","06887","BK0188"],"gpt_icon":0},{"id":"2555099028","title":"新股消息 | 東陽光藥(06887)完成港股創新式資本運作 將於8月7日登陸港交所主板","url":"https://stock-news.laohu8.com/highlight/detail?id=2555099028","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555099028?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 11:44","pubTimestamp":1753847095,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月29日，东阳光长江药业完成最后一个交易日，正式启动港股市场首例“H股吸收合并私有化+介绍上市”的创新资本运作。按计划，公司将于8月7日以“东阳光药”为主体登陆港交所主板，开创中国创新药企资产证券化新范式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","HSCEI","06887","HEXmain","HSTECH","YANG"],"gpt_icon":1},{"id":"2553988062","title":"上市生效決議獲近乎全票贊成通過，東陽光藥(06887)登陸港股進入最後倒計時","url":"https://stock-news.laohu8.com/highlight/detail?id=2553988062","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553988062?lang=zh_tw&edition=fundamental","pubTime":"2025-07-23 10:19","pubTimestamp":1753237194,"startTime":"0","endTime":"0","summary":"在6月29日发布公告宣布向联交所申请批准上市及买卖后，东阳光药——这家国内创新药龙头企业离正式登陆港股市场只差最后一步，即要约私有化和吸收合并的生效条件在临时股东大会及H股类别股东大会上获股东投票表决通过。届时，东阳光药将于今年8月7日(星期四)上午九时正在联交所开始买卖。由此可见，东阳光药的这一港股首创上市方案对股东权益的高度重视与维护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","HSCEI","BK4614","HSTECH","YANG"],"gpt_icon":1},{"id":"2553764484","title":"東陽光長江藥業(01558)與東陽光藥的合併協議獲股東大會通過 預計東陽光藥將於8月7日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2553764484","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553764484?lang=zh_tw&edition=fundamental","pubTime":"2025-07-21 19:11","pubTimestamp":1753096291,"startTime":"0","endTime":"0","summary":"东阳光长江药业(01558)及要约人广东东阳光药业股份有限公司联合公布，有关以吸收...","market":"fut","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_22.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_22.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","01558","06887","BK1515"],"gpt_icon":0},{"id":"2549854673","title":"載譽而歸，東陽光藥(06887)發明專利斬獲湖北專利金獎！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549854673","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549854673?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:42","pubTimestamp":1751971349,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月7日，湖北省知识产权局公布了第二届湖北专利奖授奖决定。东阳光药发明专利“作为丙型肝炎抑制剂的桥环化合物及其制备方法”荣获第二届湖北专利金奖。此次，发明专利“作为丙型肝炎抑制剂的桥环化合物及其制备方法”荣获本届湖北专利金奖，不仅凸显了磷酸依米他韦的突破性创新与显著临床价值，更印证了东阳光药在新药研发领域持续的创新能力与核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}